eprintid: 10175867
rev_number: 6
eprint_status: archive
userid: 699
dir: disk0/10/17/58/67
datestamp: 2023-08-30 15:12:31
lastmod: 2023-08-30 15:12:31
status_changed: 2023-08-30 15:12:31
type: article
metadata_visibility: show
sword_depositor: 699
creators_name: Gonçalves, Lisa
creators_name: Gonçalves, Duarte
creators_name: Esteban-Casanelles, Teresa
creators_name: Barroso, Tiago
creators_name: Soares de Pinho, Inês
creators_name: Lopes-Brás, Raquel
creators_name: Esperança-Martins, Miguel
creators_name: Patel, Vanessa
creators_name: Torres, Sofia
creators_name: Teixeira de Sousa, Rita
creators_name: Mansinho, André
creators_name: Costa, Luís
title: Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes
ispublished: pub
divisions: UCL
divisions: B03
divisions: C03
divisions: F24
keywords: Cancer, chronobiology, circadian, immunotherapy, melanoma
note: This work is licensed under a Creative Commons Attribution 4.0 International License. The images
or other third-party material in this article are included in the Creative Commons license,
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/
abstract: Although the impact of circadian timing on immunotherapy has yet to be integrated into clinical practice, chronoimmunotherapy is an emerging and promising field as circadian oscillations are observed in immune cell numbers as well as the expression of immunotherapy targets, e.g., programmed cell death protein-1 and its ligand programmed death ligand 1. Concurrent retrospective studies suggest that morning infusions may lead to higher effectiveness of immune checkpoint inhibitors in melanoma, non-small cell lung cancer, and kidney cancer. This paper discusses the results of a retrospective study (2016-2022) exploring the impact of infusion timing on the outcomes of all 73 patients with stage IV melanoma receiving immunotherapy at a particular medical center. While the median overall survival (OS) was 24.2 months (95% confidence interval [CI] 9.04-39.8), for a median follow-up of 15.3 months, our results show that having more than 75% of infusions in the afternoon results in shorter median OS (14.9 vs. 38.1 months; hazard ratio 0.45 [CI 0.23-0.86]; p < 0.01) with more expressive impacts on particular subgroups: women, older patients, and patients with a lower tumor burden at the outset of immunotherapy. Our findings highlight the potential benefits of follow-up validation in prospective and translational randomized studies.
date: 2023-08-15
date_type: published
publisher: MDPI AG
official_url: https://doi.org/10.3390/cells12162068
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 2080940
doi: 10.3390/cells12162068
medium: Electronic
pii: cells12162068
lyricists_name: Goncalves Dias Da Silva, Duarte
lyricists_id: DGONC71
actors_name: Flynn, Bernadette
actors_id: BFFLY94
actors_role: owner
full_text_status: public
publication: Cells
volume: 12
number: 16
article_number: 2068
event_location: Switzerland
citation:        Gonçalves, Lisa;    Gonçalves, Duarte;    Esteban-Casanelles, Teresa;    Barroso, Tiago;    Soares de Pinho, Inês;    Lopes-Brás, Raquel;    Esperança-Martins, Miguel;                     ... Costa, Luís; + view all <#>        Gonçalves, Lisa;  Gonçalves, Duarte;  Esteban-Casanelles, Teresa;  Barroso, Tiago;  Soares de Pinho, Inês;  Lopes-Brás, Raquel;  Esperança-Martins, Miguel;  Patel, Vanessa;  Torres, Sofia;  Teixeira de Sousa, Rita;  Mansinho, André;  Costa, Luís;   - view fewer <#>    (2023)    Immunotherapy around the Clock: Impact of Infusion Timing on Stage IV Melanoma Outcomes.                   Cells , 12  (16)    , Article 2068.  10.3390/cells12162068 <https://doi.org/10.3390/cells12162068>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10175867/1/cells-12-02068.pdf